Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Nuvation Bio Inc.NYSE: NUVB
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation turns negative
Q2 FY2026 stock-based compensation was -$9.03M, compared with $12.03M a year earlier. Trailing-twelve-month stock-based compensation was -$19.89M. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Stock-based compensation amounted to 57.1% of revenue in FY2025, down 352.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near -$9.03M or moves back toward the trailing-twelve-month quarterly average of -$4.97M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 35.89M USD
- Year-over-year change
- +11.2%
- 4-year CAGR
- +40.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.89M | +11.2% |
| FY2024 | 2024-12-31 | 32.28M | +65.4% |
| FY2023 | 2023-12-31 | 19.51M | +19.8% |
| FY2022 | 2022-12-31 | 16.29M | +75.8% |
| FY2021 | 2021-12-31 | 9.27M | — |
Stock-Based Compensation vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 stock-based compensation of $19.89M is the 8th largest of the 11 companies compared; the peer median is $43.55M.
- Its year-over-year change of -153.0% is the lowest of 11, against a peer median of +0.5%.
- Stock-based compensation amounts to 11.7% of revenue for NUVB, versus a peer median of 92.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $53.61M | +38.3% | +30.9% | 75.4% | |
| LTM Jun 2026 | $51.48M | +103.6% | +125.9% | — | |
| LTM Jun 2026 | $49.78M | +71.5% | +62.2% | — | |
| LTM Sep 2026 | $48.87M | -15.9% | +4.1% | 72.0% | |
| LTM Mar 2026 | $48.31M | +35.8% | +36.5% | 92.8% | |
| LTM Mar 2026 | $38.79M | +1.8% | +32.7% | 179.5% | |
| LTM Sep 2026 | $36.81M | -0.7% | — | 32869.6% | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
| LTM Mar 2026 | $18.36M | -5.7% | -19.7% | 101.5% | |
| LTM Jun 2026 | $7.89M | -59.1% | -23.1% | 2.5% | |
| LTM Sep 2026 | $1.76M | -94.6% | +47.1% | — | |
| Peer median (excluding NUVB) | $43.55M | +0.5% | +32.7% | 92.8% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.